A new role for epidermal cell-derived thymocyte activating factor/IL-1 as an antagonist for distinct epidermal cell function.
It is known that many immunologic responses to IL-1 are antagonized by the neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH). This led us to investigate the possible reciprocal effects of IL-1 and the functionally related epidermal cytokines, epidermal cell-derived thymocyte activating factor (ETAF) and IL-6, on the melanogenic effect of alpha-MSH on murine Cloudman melanoma cells. When these cells were treated with ETAF in combination with alpha-MSH or its potent analog [Nle4,D-Phe7]-alpha-MSH, the melanotropin induced increase in tyrosinase activity, and thus melanin synthesis, was abrogated. This inhibitory effect of ETAF was not mediated by competitive binding to the melanotropin receptor, because ETAF also blocked the melanogenic response of melanoma cells to isobutyl methylxanthine (IBMX) and to PGE1 and PGE2. ETAF had no effect on cellular proliferation. Inhibition of the stimulated tyrosinase activity by ETAF was not due to diminished cAMP synthesis or increased cAMP degradation. Cells treated concomitantly with ETAF and alpha-MSH, IBMX, or PGE1 had the same cAMP levels as cells treated with alpha-MSH, IBMX, or PGE1 alone. In contrast to ETAF, human rIL-1 alpha or IL-1 beta alone or in combination did not have an inhibitory effect on melanogenesis. IL-6 significantly inhibited the basal level of tyrosinase and partially abrogated the alpha-MSH-induced tyrosinase activity. IL-6 also stimulated cellular proliferation when added alone or in combination with alpha-MSH. Granulocyte-macrophage colony stimulating factor (GM-CSF) did not alter either the tyrosinase activity or cellular replication at the concentrations tested. IL-1 alpha, GM-CSF, and IL-6 or IL-1 alpha and GM-CSF added together did not significantly affect the MSH-induced tyrosinase activity. These results ascribe a new potential function for ETAF and IL-6 as modulators of the melanogenic response of pigment cells.
Swope
V B
VB
University of Cincinnati College of Medicine, Department of Dermatology, OH 45267-0592.
Abdel-Malek
Z A
ZA
Sauder
D N
DN
Nordlund
J J
JJ
D015056:1-Methyl-3-isobutylxanthine / Q000037:antagonists & inhibitors; D000527:Alprostadil / Q000037:antagonists & inhibitors; D000818:Animals; D002460:Cell Line; D003115:Colony-Stimulating Factors / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D015232:Dinoprostone / Q000037:antagonists & inhibitors; D004817:Epidermis / Q000187:drug effects* / Q000502:physiology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006133:Growth Substances / Q000494:pharmacology; D007375:Interleukin-1 / Q000502:physiology*; D015850:Interleukin-6; D007378:Interleukins / Q000494:pharmacology; D008545:Melanoma / Q000201:enzymology* / Q000378:metabolism; D051379:Mice; D014442:Monophenol Monooxygenase / Q000378:metabolism; D000521:alpha-MSH / Q000037:antagonists & inhibitors
D003115:Colony-Stimulating Factors; D006133:Growth Substances; D007375:Interleukin-1; D015850:Interleukin-6; D007378:Interleukins; D000521:alpha-MSH; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000242:Cyclic AMP; D014442:Monophenol Monooxygenase; D000527:Alprostadil; D015232:Dinoprostone; D015056:1-Methyl-3-isobutylxanthine